NCT05903937 (HAITILS-PHP) is a Phase 1 clinical trial of Autologous Tumor Infiltrating Lymphocytes in Uveal Melanoma, sponsored by Vastra Gotaland Region.

Who is sponsoring NCT05903937?

NCT05903937 is sponsored by Vastra Gotaland Region.

What drugs are being tested in NCT05903937?

Interventions in NCT05903937: Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2.

What condition does NCT05903937 study?

NCT05903937 studies Uveal Melanoma, Metastatic Cutaneous Melanoma.

Is NCT05903937 still recruiting?

NCT05903937 is currently not yet recruiting. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT05903937: HAITILS-PHP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

Not yet recruiting Phase 1 Last updated 15 June 2023

What this trial tests

Phase 1 trial testing Autologous Tumor Infiltrating Lymphocytes in Uveal Melanoma in 6 participants. Not yet recruiting.

Timeline

31 December 2023

Primary endpoint
31 December 2024

31 December 2029

Quick facts

Lead sponsor	Vastra Gotaland Region
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	31 December 2023
Primary completion	31 December 2024
Estimated completion	31 December 2029

Drugs / interventions tested

Autologous Tumor Infiltrating Lymphocytes — full drug profile →
Melphalan (melphalan) — full drug profile →
Interleukin-2

Conditions studied

Uveal Melanoma — all drugs for Uveal Melanoma →
Metastatic Cutaneous Melanoma — all drugs for Metastatic Cutaneous Melanoma →

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Uveal Melanoma or Metastatic Cutaneous Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic approaches to enhance natural killer cell cytotoxicity.
Stenger TD, Miller JS. · · 2024 · cited 14× · PMID 38545115 · DOI 10.3389/fimmu.2024.1356666
Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances.
Kulbay M, Tuli N, Mazza M, Jaffer A, et al · · 2025 · cited 8× · PMID 39857692 · DOI 10.3390/biomedicines13010108
Advances and Challenges in Immunotherapy for Metastatic Uveal Melanoma: Clinical Strategies and Emerging Targets.
Grigoruta M, Kong X, Qin Y. · · 2025 · cited 1× · PMID 40725830 · DOI 10.3390/jcm14145137

Verify or expand the search:

Other trials of Autologous Tumor Infiltrating Lymphocytes

Trials testing the same drug.

NCT06473961 — A Phase Ib Study of GC101 in NSCLC · Phase 1 · recruiting
NCT04812470 — Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases · Phase 1 · completed
NCT03991741 — Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors · Phase 1 · terminated
NCT06084299 — Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer · Phase 1 · recruiting

Other recruiting trials for Uveal Melanoma

Currently open trials in the same condition.

NCT07421739 — Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects · recruiting
NCT06070012 — Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06932757 — Adjuvant Quisinostat in High-Risk Uveal Melanoma · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
NCT06519266 — PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases · Phase 3 · recruiting

Other Vastra Gotaland Region trials

Trials by the same sponsor.

NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
NCT07472335 — Home-based Acute Care for Older Persons Initiated by the Emergency Medical and Ambulance Services - a Retrospective Obse · not yet recruiting
NCT07246577 — The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant C · recruiting
NCT07449338 — Prospective Cohort Study of Response and Tolerability of Accelerated Intermittent Theta-burst Stimulation (1W-AiTBS) · not yet recruiting
NCT07334340 — Modified vs Standard CDED: Evaluation of a Nordic Adaptation of Nutritional Therapy in Paediatric Crohn's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05903937 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vastra Gotaland Region
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05903937.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing